FBDB™ platform
HanchorBio dedicates to develop biological medicines with simultaneous multi-targeting through a novel IgG Fc-Based Designer Biologics (FBDB™) platform. We aim to achieve the holistic effect of all participating modalities to overcome the shortcomings of the CPI therapies.
Innovative Research (Lead Discovery & Optimization)
- Novel target research and evaluation
- Antibody selections from hybridomas or phage library
- Antibody & Protein engineering; Development of designer proteins
- Development of in vitro and in vivo assays/models for evaluating the bioactivities of anti-cancer drugs
- MOA studies
In Vivo Pharmacology Study
Establishment of various syngeneic, xenograft and humanized mouse models for evaluating the efficacy of anti-cancer drugs
Lab-Scale Process Development
- Cell line development and RCB establishment
- Cell culture process development and optimization
- Purification process development and optimization
- Formulation development
- Assay method development
- CQA, CPP determination
CMC and submission
- Consideration of safety, quality and efficacy during development and CMC stages.
- Scale-up, technical transfer and method transfer ability
- Readiness of technical documents for filing
